| sitagliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs control (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs glimepiride (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs pioglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.84 [0.43 1.65] | p=1.00 | 0 | 576 | 2 | Goldstein,Hanefeld, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (add on insulin+/-MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.02 [0.61 1.68] | p=1.00 | 0 | 2058 | 3 | Charbonnel,Nauck,Scott** (sit vs pbo on top met), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (add on PIO) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (on top PIO) | No demonstrated result Adverse events leading to treatment discontinuation by 459% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 5.59 [1.22 25.62] | p=0.04 | 0 | 353 | 1 | Rosenstock (sit on top pio vs pbo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (on-top glimepiride+/- metformine) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 2.74 [0.28 26.77] | p=1.00 | 0 | 222 | 1 | Hermansen, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs rosiglitazone (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs Sulphonylurea (on top MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin 50mg bid monotherapy vs glipizide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin 50mg bid monotherapy vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 3.07 [0.32 29.97] | p=1.00 | 0 | 247 | 1 | Scott* (sit vs pbo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin monotherapy vs metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin monotherapy vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.68 [0.29 1.57] | p=1.00 | 0 | 958 | 3 | Aschner,Nonaka,Raz, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin monotherapy vs voglibose | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin+pio vs metformin+pio | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All types of patients: 29 trials - Aschner - Goldstein - Hanefeld - Nonaka - Raz - Scott* (sit vs pbo) - Goldstein (sit vs met) - Scott* (sit vs glipi) - Charbonnel - Goldstein (sit+met vs met) - Hermansen - Nauck - Rosenstock (sit on top pio vs pbo) - Scott** (sit vs pbo on top met) - Al Sifri - Pérez-Monteverde - Stafford - Barzilai - Reasner - Arechavaleta - Iwamoto - Vilsbøll - Aschner - Derosa - Rigby - Mohan - Chan - raz - Rosenstock
| sitagliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs control (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs glimepiride (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs pioglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.84 [0.43 1.65] | p=1.00 | 0 | 576 | 2 | Goldstein,Hanefeld, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (add on insulin+/-MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.02 [0.61 1.68] | p=1.00 | 0 | 2058 | 3 | Charbonnel,Nauck,Scott** (sit vs pbo on top met), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (add on PIO) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (on top PIO) | No demonstrated result Adverse events leading to treatment discontinuation by 459% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 5.59 [1.22 25.62] | p=0.04 | 0 | 353 | 1 | Rosenstock (sit on top pio vs pbo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (on-top glimepiride+/- metformine) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 2.74 [0.28 26.77] | p=1.00 | 0 | 222 | 1 | Hermansen, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs rosiglitazone (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs Sulphonylurea (on top MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin 50mg bid monotherapy vs glipizide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin 50mg bid monotherapy vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 3.07 [0.32 29.97] | p=1.00 | 0 | 247 | 1 | Scott* (sit vs pbo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin monotherapy vs metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin monotherapy vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.68 [0.29 1.57] | p=1.00 | 0 | 958 | 3 | Aschner,Nonaka,Raz, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin monotherapy vs voglibose | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin+pio vs metformin+pio | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on metformin: 3 trials - Charbonnel - Nauck - Scott** (sit vs pbo on top met)
| sitagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.02 [0.61 1.68] | p=1.00 | 0 | 2058 | 3 | Charbonnel,Nauck,Scott** (sit vs pbo on top met), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on monotherapy : 4 trials - Charbonnel - Nauck - Rosenstock (sit on top pio vs pbo) - Scott** (sit vs pbo on top met)
| sitagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.02 [0.61 1.68] | p=1.00 | 0 | 2058 | 3 | Charbonnel,Nauck,Scott** (sit vs pbo on top met), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sitagliptin vs placebo (on top PIO) | No demonstrated result Adverse events leading to treatment discontinuation by 459% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 5.59 [1.22 25.62] | p=0.04 | 0 | 353 | 1 | Rosenstock (sit on top pio vs pbo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with insufficient glycaemic control with bitherapy: 1 trials - Hermansen
| sitagliptin vs placebo (on-top glimepiride+/- metformine) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 2.74 [0.28 26.77] | p=1.00 | 0 | 222 | 1 | Hermansen, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
